FDA Approves Pfizer-BioNTech XFG-Adapted COVID Vaccine for Fall 2026
PFE sits 19% above its 52-week low of $23.58.
Summary
The FDA approved the supplemental BLA for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine targeting the XFG variant. The approval covers adults 65 and older and high-risk individuals 5-64. Shipping begins immediately with availability in pharmacies and clinics within days. This is a routine seasonal update but confirms Pfizer's continued participation in the COVID vaccine market. The approval follows the FDA's May guidance selecting XFG as the preferred composition. For BioNTech, this reinforces its mRNA platform and revenue stream from the collaboration.
At the time of this announcement, PFE was trading at $28.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $159.7B. The 52-week trading range was $23.58 to $28.75. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.